Dr. Elihu Estey is an expert in treating patients with acute myeloid leukemia, or AML, and myelodysplastic syndrome, a bone marrow disorder. His research focuses on designing clinical trials that address the complexities of medical practice and patients’ wishes. For example, trials typically only study one primary outcome, such as the toxic side effects of a drug. Yet physicians and patients are often concerned with several outcomes. They might be willing to accept a slightly more toxic drug if the increase in toxicity was more than offset by an increase in survival. Dr. Estey designs trials that can monitor multiple outcomes, such as both survival and toxicity, particularly in AML, in which outcomes are known relatively quickly.